• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

严重程度、关键性和严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）β变异株的致死性。

Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.

机构信息

Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar.

World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar.

出版信息

Clin Infect Dis. 2022 Aug 24;75(1):e1188-e1191. doi: 10.1093/cid/ciab909.

DOI:10.1093/cid/ciab909
PMID:34657152
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9402694/
Abstract

Beta (B.1.351)-variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19-related death were 1.24-fold (1.11-1.39), 1.49-fold (1.13-1.97), and 1.57-fold (1.03-2.43) higher, respectively, for the Beta variant.

摘要

在卡塔尔对贝塔（B.1.351）变体的 2019 冠状病毒病（COVID-19）进行了研究。与阿尔法（B.1.1.7）变体相比，贝塔变体进展为重症疾病、危重症疾病和 COVID-19 相关死亡的几率（95%置信区间）分别高 1.24 倍（1.11-1.39）、1.49 倍（1.13-1.97）和 1.57 倍（1.03-2.43）。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40e3/9402694/8386c71e2adf/ciab909_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40e3/9402694/8386c71e2adf/ciab909_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40e3/9402694/8386c71e2adf/ciab909_fig1.jpg

相似文献

1
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant.严重程度、关键性和严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）β变异株的致死性。
Clin Infect Dis. 2022 Aug 24;75(1):e1188-e1191. doi: 10.1093/cid/ciab909.
2
Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar.在卡塔尔感染 SARS-CoV-2 的德尔塔变异株和贝塔变异株患者的疾病严重程度。
JAMA Intern Med. 2022 Feb 1;182(2):197-205. doi: 10.1001/jamainternmed.2021.7949.
3
Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant.2019 年冠状病毒病在感染奥密克戎变异株的儿童中的严重程度。
Clin Infect Dis. 2022 Aug 24;75(1):e361-e367. doi: 10.1093/cid/ciac275.
4
Susceptibility of Domestic Goat () to Experimental Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.351/Beta Variant.家养山羊对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) B.1.351/β 变异株的易感性。
Viruses. 2022 Sep 9;14(9):2002. doi: 10.3390/v14092002.
5
COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar.卡塔尔感染奥密克戎变异株与感染德尔塔变异株的患者 COVID-19 疾病严重程度比较。
J Glob Health. 2022 Jul 6;12:05032. doi: 10.7189/jogh.12.05032.
6
Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis.妊娠期冠状病毒谱感染（SARS、MERS、COVID-19）结局的系统评价和荟萃分析。
Am J Obstet Gynecol MFM. 2020 May;2(2):100107. doi: 10.1016/j.ajogmf.2020.100107. Epub 2020 Mar 25.
7
Two Cases of Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections Caused by the Omicron Variant (B.1.1.529 Lineage) in International Travelers to Japan.两例入境日本的国际旅行者感染奥密克戎变异株（B.1.1.529 谱系）导致的突破性严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染
Clin Infect Dis. 2022 Aug 24;75(1):e354-e356. doi: 10.1093/cid/ciab1072.
8
Increased Mortality Among Persons With Symptomatic Coronavirus Disease 2019 (COVID-19) During the Period of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.617.2 (Delta Variant) Predominance: Alaska, November 2020-October 2021.2020 年 11 月至 2021 年 10 月期间，严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）B.1.617.2（德尔塔变体）流行期间，有症状的 2019 年冠状病毒病（COVID-19）患者死亡率增加：阿拉斯加。
Clin Infect Dis. 2022 Oct 3;75(Suppl 2):S298-S302. doi: 10.1093/cid/ciac530.
9
SARS-CoV-2 B.1.1.7 Variant Infection in Malayan Tigers, Virginia, USA.美国弗吉尼亚州，马来亚虎感染 SARS-CoV-2 B.1.1.7 变体。
Emerg Infect Dis. 2021 Dec;27(12):3171-3173. doi: 10.3201/eid2712.211234.
10
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异相关受体结合域（RBD）突变对2019冠状病毒病（COVID-19）感染或疫苗接种所诱导血清抗体易感性的影响
Clin Infect Dis. 2022 May 3;74(9):1623-1630. doi: 10.1093/cid/ciab656.

引用本文的文献

1
Quantitatively analyzing the relationship between non-pharmaceutical interventions and the direction of virus evolution using a dynamic model.使用动态模型定量分析非药物干预措施与病毒进化方向之间的关系。
Front Public Health. 2025 May 9;13:1542759. doi: 10.3389/fpubh.2025.1542759. eCollection 2025.
2
Evaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in Qatar.评估医院入院数据作为新冠病毒疾病严重程度的指标：卡塔尔的一项全国性评估。
Open Forum Infect Dis. 2025 Feb 17;12(3):ofaf098. doi: 10.1093/ofid/ofaf098. eCollection 2025 Mar.
3
Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar.

本文引用的文献

1
One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar.SARS-CoV-2 研究进展一年：卡塔尔新冠疫情爆发的基因组特征分析。
Front Cell Infect Microbiol. 2021 Nov 17;11:768883. doi: 10.3389/fcimb.2021.768883. eCollection 2021.
2
Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar.通过高通量多重PCR进行实时SARS-CoV-2基因分型揭示卡塔尔关注变异株的流行病学情况。
Int J Infect Dis. 2021 Nov;112:52-54. doi: 10.1016/j.ijid.2021.09.006. Epub 2021 Sep 12.
3
SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar.
新冠疫情期间COVID-19严重程度和死亡率的转折点：卡塔尔的一项全国队列研究
BMJ Public Health. 2023 Oct 29;1(1):e000479. doi: 10.1136/bmjph-2023-000479. eCollection 2023 Nov.
4
Genomic Surveillance of SARS-CoV-2 in Taiwan: A Perspective on Evolutionary Data Interpretation and Sequencing Issues.台湾地区严重急性呼吸综合征冠状病毒2的基因组监测：进化数据解读与测序问题的视角
Biomed J. 2024 Nov 26:100820. doi: 10.1016/j.bj.2024.100820.
5
The Clinical Severity of COVID-19 Variants of Concern: Retrospective Population-Based Analysis.关注的 COVID-19 变异株的临床严重程度：回顾性基于人群的分析。
JMIR Public Health Surveill. 2024 Aug 27;10:e45513. doi: 10.2196/45513.
6
A cryptic site in class 5 epitope of SARS-CoV-2 RBD maintains highly conservation across natural isolates.严重急性呼吸综合征冠状病毒2受体结合域（SARS-CoV-2 RBD）5类表位中的一个隐蔽位点在天然分离株中保持高度保守。
iScience. 2024 Jun 11;27(7):110208. doi: 10.1016/j.isci.2024.110208. eCollection 2024 Jul 19.
7
Integration of individualized and population-level molecular epidemiology data to model COVID-19 outcomes.整合个体化和人群水平的分子流行病学数据来建立 COVID-19 结局模型。
Cell Rep Med. 2024 Jan 16;5(1):101361. doi: 10.1016/j.xcrm.2023.101361.
8
Descriptive epidemiology of SARS-CoV-2 Beta (B.1.351) variant cases in England, December 2020 to June 2022.2020 年 12 月至 2022 年 6 月期间英国 SARS-CoV-2 贝塔（B.1.351）变异株病例的描述性流行病学研究。
Influenza Other Respir Viruses. 2023 Nov;17(11):e13204. doi: 10.1111/irv.13204.
9
SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study.SARS-CoV-2 感染以及年龄、性别、合并症和疫苗接种对老年人的影响：一项全国队列研究。
Influenza Other Respir Viruses. 2023 Nov;17(11):e13224. doi: 10.1111/irv.13224.
10
From Emergence to Endemicity: A Comprehensive Review of COVID-19.从出现到地方性流行：对新冠病毒病的全面综述
Cureus. 2023 Oct 31;15(10):e48046. doi: 10.7759/cureus.48046. eCollection 2023 Oct.
卡塔尔的 SARS-CoV-2 感染住院率、严重程度、危急程度和病死率。
Sci Rep. 2021 Sep 14;11(1):18182. doi: 10.1038/s41598-021-97606-8.
4
Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study.南非第一波和第二波期间因 COVID-19 住院的个体的死亡率差异：一项队列研究。
Lancet Glob Health. 2021 Sep;9(9):e1216-e1225. doi: 10.1016/S2214-109X(21)00289-8. Epub 2021 Jul 9.
5
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.mRNA-1273 新冠病毒疫苗对卡塔尔 B.1.1.7 和 B.1.351 变异株及重症新冠疾病的有效性
Nat Med. 2021 Sep;27(9):1614-1621. doi: 10.1038/s41591-021-01446-y. Epub 2021 Jul 9.
6
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.BNT162b2新冠疫苗对B.1.1.7和B.1.351变异株的有效性
N Engl J Med. 2021 Jul 8;385(2):187-189. doi: 10.1056/NEJMc2104974. Epub 2021 May 5.
7
Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021.关注的 SARS-CoV-2 变体 B.1.1.7、B.1.351 或 P.1 的特征：来自七个欧盟/欧洲经济区国家的数据，2020 年第 38 周至 2021 年第 10 周。
Euro Surveill. 2021 Apr;26(16). doi: 10.2807/1560-7917.ES.2021.26.16.2100348.
8
Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic.描述卡塔尔严重阶段 SARS-CoV-2 疫情特征。
Sci Rep. 2021 Mar 18;11(1):6233. doi: 10.1038/s41598-021-85428-7.
9
Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study.202012/1 感染关注的 SARS-CoV-2 变异株的患者的死亡率风险：匹配队列研究。
BMJ. 2021 Mar 9;372:n579. doi: 10.1136/bmj.n579.